Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
McKinsey
Chubb
Fish and Richardson
US Army
Johnson and Johnson
Federal Trade Commission
Fuji
Deloitte

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,161,926

« Back to Dashboard

Which drugs does patent 9,161,926 protect, and when does it expire?


Patent 9,161,926 protects ACZONE and is included in one NDA. There has been one Paragraph IV challenge on Aczone.

This patent has ten patent family members in eleven countries.

Summary for Patent: 9,161,926

Title:Topical dapsone and dapsone/adaplene compositions and methods for use thereof
Abstract: Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.
Inventor(s): Warner; Kevin S. (Anaheim, CA), Parashar; Ajay P. (San Diego, CA), Swaminathan; Vijaya (San Francisco, CA), Bhatt; Varsha (San Francisco, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:14/082,955
Patent Claim Types:
see list of patent claims
Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Allergan Inc
ACZONE
dapsone
GEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,161,926

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,517,219Topical dapsone and dapsone/adapalene compositions and methods for use thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,161,926

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2015123207► Subscribe
Mexico2015006396► Subscribe
South Korea20150085069► Subscribe
Japan2016500072► Subscribe
Hong Kong1214516► Subscribe
European Patent Office2922528► Subscribe
Denmark2922528► Subscribe
China105246457► Subscribe
Canada2890224► Subscribe
Australia2013348247► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Moodys
Fuji
QuintilesIMS
Fish and Richardson
US Department of Justice
Mallinckrodt
Covington
Argus Health
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot